Pre-Market Edge: Get a Jump on Profitable Plays!

Sponsored by

You are receiving this newsletter as a subscriber to Premium Stock Alerts

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Looking for visuals and charts, rather than words, to understand the daily news?

Bay Area Times is a visual-based newsletter on business and tech, with 250,000+ subscribers.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


Sponsored

New Trading Approach Produces 100% Win-Rate in Q1

See how one trader has produced a 100% win-rate (over 27 trades) and an average gain of 39% every 3 days.

SHOW ME THE PROOF

Happening Today

✓ 08:30 AM ET – Initial Jobless Claims

✓ 08:30 AM ET – Philadelphia Fed Manufacturing Index (May)

✓ 08:30 AM ET – Building Permits (Apr)

✓ 08:30 PM ET – Housing Starts (Apr)

PREMARKET SNAPSHOT 📈

Stock Futures are pointing to a positive open with the NASDAQ 100 leading the way with a gain of nearly 1.5%.

S&P500

$5308.15 

⬆️ 1.17%

Dow

$39908

⬆️ 0.88%

NASDAQ

$18596.65 

⬆️ 1.49% 

SECTOR SNAPSHOT 

Information Technology leads the gainers today with a 2.29% increase, while Consumer Discretionary remains flat.

NAME

PRICE

%CHANGE

Consumer Discretionary

1,458.87

UNCH

Consumer Staples

824.35

0.02% 🟢

Energy

714.93

0.15% 🟢

Financials

700.75

0.72% 🟢

Health Care

1,702.06

1.44% 🟢

Industrials

1,064.67

0.63% 🟢

Materials

579.14

0.16% 🟢

Real Estate

243.14

1.69% 🟢

Information Technology

3,929.19

2.29% 🟢

Communication Services

295.88

0.91% 🟢

Utilities

367.15

1.41% 🟢


Sponsored

Trading Experts Call It 'The Perfect Tesla Trade'

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less.

New research shows it's happened 23 different times this year.

The next trade is scheduled for this Thursday.

Click here for details

Unusual Volume

📈 SINTX Technologies Inc (SINT) jumped 132.00% to $0.13 on a whopping 1.0 billion shares traded.

📈 Investors went wild, sending Greenwave Technology Solutions Inc (GWAV) stock soaring 34.38% to $0.06 on a massive volume of 822.84 million shares.

📈 Abnormal activity shook Crown ElectroKinetics Corp (CRKN), pushing it down -2.94% to $0.05 on a whopping 523.61 million shares traded.

📈 Selina Hospitality PLC. (SLNA) stock recently closed 118.57% upper at $0.12 on substantial volume of 501.74 million shares.

📈 AMC Entertainment Holdings Inc (AMC) decrease by -20.00% in a single trading session, with abnormally high trading volume of 309.6 million shares.


Sponsored

Copper is booming. Follow the smart-money into this 10-cent copper stock

Copper just broke above $4.40 per pound with supply struggling to keep pace with rising demand in the clean energy transition.

Smart investors are piling into the best small-cap copper stocks with high-grade projects in ultra-safe, Tier-1 mining jurisdictions such as Canada.

This 10-cent small-cap is advancing its flagship Canadian project with around a billion pounds of copper already confirmed.

Find out more here.

Premarket Movers

Blue Star Foods Corp. (BSFC) experiences a substantial 25.89% surge in pre-market trading after announcing 1-for-50 reverse stock split.

Cyngn Inc. (CYN) sees a significant 40.21% increase, reaching a pre-market price of $0.12. The company shared several commercial and technological accomplishments from the first quarter of 2024.

AST SpaceMobile, Inc. (ASTS) demonstrates a noteworthy 31.38% surge, with a pre-market price of $3.14 after providing business update and first quarter 2024 results.

Pre Market Gainers

Pre Market Change

Pre Market Volume

BSFC

+25.89%

16.19M

CYN

+40.21%

13.22M

BRSH

+12.40%

4.49M

AKAN

+6.92%

2.52M

ASTS

+32.64%

1.77M

BURU

+17.76%

1.60M

ASTI

+14.55%

1.16M

GNS

+4.81%

884.91K

WMT

+4.46%

829.47K

SCPX

+12.74%

743.15K


Sponsored

Average Traders Only Have A 10% Chance Of Success

Did you know that over 90% of all investors fail within their first year on the market?

It's not a coincidence - it's a trap - laid by Wall Street. 

But investing expert Tom Busby's free guide reveals the strategies you need to thrive!

Click here to download your free copy of Busby's "Little Black Book", now!

Important FDA 

Recently Announced

Dynavax Technologies Corp (DVAX) received feedback on their drug HEPLISAV-B on May 14th, 2024. The FDA requested additional information for expanding HEPLISAV-B vaccination to include adults undergoing hemodialysis.

Day One Biopharmaceuticals (DAWN) is cheering as their drug Tovorafenib, now under the brand name OJEMDA, secured FDA approval. This medication provides new hope for children battling a specific type of brain tumor: relapsed or progressive pediatric low-grade glioma.

X Pharmaceuticals (XFOR) can also celebrate as their drug Mavorixafor, known commercially as XOLREMDI, received FDA approval. This medication offers a novel approach to treating WHIM syndrome, a rare and challenging condition affecting people twelve years of age and older.

Neurocrine Biosciences Inc (NBIX) has expanded the availability of their existing medication Ingrezza. The FDA recently approved a new sprinkle formulation, making it easier for adults with tardive dyskinesia and chorea associated with Huntington's disease to take their medication.

Upcoming Announcements

Bristol-Myers Squibb Co. (BMY) investors should mark their calendars for May 23rd, 2024. That's the date the Food and Drug Administration (FDA) will announce its decision on Breyanzi, a treatment the company offers for patients with relapsed or refractory follicular lymphoma.

Separately, Novo Nordisk A/S (NVO) is also awaiting an FDA decision, but this time from a panel of experts. On May 24th, the panel will convene to review Awiqli (Insulin Icodec), the company's treatment for adult diabetes.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Sponsored
Bullseye Trades Get free daily HOT STOCK & Options trading ideas with real-money 💰 TRADE ALERTS from trading genius, Jeff Bishop

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.